0.5925
Schlusskurs vom Vortag:
$0.6304
Offen:
$0.5967
24-Stunden-Volumen:
1.38M
Relative Volume:
1.06
Marktkapitalisierung:
$49.64M
Einnahmen:
$153.73M
Nettoeinkommen (Verlust:
$-106.79M
KGV:
-0.3329
EPS:
-1.78
Netto-Cashflow:
$-115.93M
1W Leistung:
-19.93%
1M Leistung:
-58.71%
6M Leistung:
-83.22%
1J Leistung:
-88.36%
Sutro Biopharma Inc Stock (STRO) Company Profile
Firmenname
Sutro Biopharma Inc
Sektor
Branche
Telefon
650-392-8412
Adresse
111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie STRO mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
STRO
Sutro Biopharma Inc
|
0.5925 | 49.64M | 153.73M | -106.79M | -115.93M | -1.78 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 124.29B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 68.39B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
590.06 | 35.99B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.93B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
264.32 | 28.47B | 3.81B | -644.79M | -669.77M | -6.24 |
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-03-17 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2025-03-14 | Herabstufung | BofA Securities | Buy → Underperform |
2025-03-14 | Herabstufung | Citizens JMP | Mkt Outperform → Mkt Perform |
2025-03-14 | Herabstufung | Wedbush | Outperform → Neutral |
2024-05-08 | Eingeleitet | BofA Securities | Buy |
2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
2023-10-06 | Eingeleitet | Oppenheimer | Outperform |
2023-03-21 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2022-08-18 | Fortgesetzt | Wells Fargo | Overweight |
2021-06-18 | Eingeleitet | H.C. Wainwright | Buy |
2020-12-03 | Eingeleitet | Stifel | Buy |
2020-09-02 | Eingeleitet | Jefferies | Buy |
2020-07-16 | Eingeleitet | Wells Fargo | Overweight |
2020-01-13 | Eingeleitet | SunTrust | Buy |
2019-10-07 | Eingeleitet | BTIG Research | Buy |
2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
2019-04-29 | Eingeleitet | H.C. Wainwright | Buy |
2018-10-22 | Eingeleitet | JMP Securities | Mkt Outperform |
2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
2018-10-22 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Sutro Biopharma Inc Aktie (STRO) Neueste Nachrichten
Sutro Biopharma stock hits 52-week low at $0.58 amid market challenges - Investing.com India
Sutro Biopharma, Inc. (NASDAQ:STRO) Receives Average Rating of “Hold” from Analysts - Defense World
Layoff Tracker: Arbutus Cuts 57% of Workforce - BioSpace
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline - Investing.com Australia
Sutro Biopharma stock hits 52-week low at $0.76 amid sharp decline By Investing.com - Investing.com South Africa
Connor Clark & Lunn Investment Management Ltd. Sells 110,734 Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) - Defense World
Sutro Biopharma lays off dozens of employees in ‘strategic portfolio review’ - MSN
Biotech company based in Peninsula laying off 90% of staff - MSN
HC Wainwright Expects Stronger Earnings for Sutro Biopharma - Defense World
Bay Area biotech company laying off 90% of staff as CEO leaves - San Francisco Chronicle
The Escalator: Stoke Therapeutics, Merck, Sutro Biopharma and more - Medical Marketing and Media
Sutro Biopharma rises after market hours on portfolio review, restructuring - MSN
Sutro Biopharma’s (STRO) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Sutro Biopharma stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Canada
This Li Auto Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga
HC Wainwright Downgrades Sutro Biopharma to Neutral From Buy, Price Target is $2 -March 17, 2025 at 08:33 am EDT - Marketscreener.com
Oppenheimer Downgrades Sutro Biopharma to Market Perform From Outperform -March 17, 2025 at 07:57 am EDT - Marketscreener.com
Deutsche Bank Adjusts Sutro Biopharma Price Target to $5 From $10, Maintains Buy Rating - Marketscreener.com
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift By Investing.com - Investing.com South Africa
Sutro Biopharma’s SWOT analysis: ADC developer’s stock faces pivotal shift - Investing.com
Sutro Biopharma (NASDAQ:STRO) Cut to Market Perform at Citizens Jmp - Defense World
Array Technologies, Nextracker, Sutro Biopharma - TradingView
Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Monday - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to Neutral at Wedbush - Defense World
Sutro Biopharma (NASDAQ:STRO) Cut to “Underperform” at Bank of America - Defense World
Sutro Biopharma Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance UK
Sutro Biopharma: Revolutionizing Cancer Treatment with Precision Therapeutics - Apna Kal
Sutro Biopharma Presents Promising Late-Stage Data for Luveltamab Tazevibulin in Platinum-Resistant Ovarian Cancer – Apnakal market - Apna Kal
Sutro Biopharma’s Luvelta Shows Promising Data in Late-Stage Ovarian Cancer Study at SGO 2025 - Apna Kal
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025 - The Manila Times
Sutro's Cancer Drug Doubles Response Rate in Latest Trial, But Faces Uncertain Future - StockTitan
Sutro Biopharma downgraded to Neutral from Overweight at Piper Sandler - Yahoo Finance
Bay Area biotech company once worth $2B guts staff, departing execs get $600K - MSN
Sutro Biopharma Prioritizes ADC Programs Amid Financial Shift - TipRanks
Cattle Post Gains on Friday, Helped by Cah Strength - The Globe and Mail
Oppenheimer cuts Sutro Biopharma stock rating to Perform By Investing.com - Investing.com Canada
Oppenheimer cuts Sutro Biopharma stock rating to Perform - Investing.com India
Jefferies cuts Sutro Biopharma target to $8, maintains Buy By Investing.com - Investing.com Canada
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Strategic Focus and Financial ... - Yahoo
Sutro Biopharma Inc (STRO) Q4 2024 Earnings Call Highlights: Str - GuruFocus.com
Longtime Peninsula biotech to chop half its jobs, CEO exitsSan Francisco Business Times - The Business Journals
Earnings call transcript: Sutro Biopharma Q4 2024 sees stock plunge - Investing.com India
Truist maintains Buy on Sutro Biopharma, removes price target By Investing.com - Investing.com UK
Sutro prioritizes preclinical ADC programs - BioWorld Online
Sutro stock drops as analysts downgrade (STRO:NASDAQ) - Seeking Alpha
Sector Update: Health Care Stocks Higher Premarket Friday -March 14, 2025 at 09:30 am EDT - Marketscreener.com
New ADC focus as Sutro slashes workforce, drops lead drug - The Pharma Letter
This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday - Benzinga
Piper Sandler Downgrades Sutro Biopharma to Neutral From Overweight, Adjusts PT to $2 From $8 - Marketscreener.com
Sutro Cuts Half of Staff, Deprioritizes ADC in Strategic Review - BioSpace
Sutro Biopharma Falls as Company Cuts Workforce, Shifts Focus to ADCs - TradingView
Finanzdaten der Sutro Biopharma Inc-Aktie (STRO)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):